Clinical Evidence Expansion

About Electromed

Electromed is a mission-driven, publicly traded medical device company with a 30-year history of dedicated innovation in airway clearance therapy. The company has achieved niche market leadership with its SmartVest system, demonstrating a proven strategy of U.S.-based manufacturing, direct-to-patient support via respiratory therapists, and continuous product refinement. Its core focus is on expanding access to its clinically validated HFCWO therapy to improve patient outcomes and reduce healthcare costs associated with chronic respiratory diseases.

About Electromedical Products International

Electromedical Products International is a long-established, privately-held medical device company focused on neuromodulation. Its core product, Alpha-Stim, delivers cranial electrotherapy stimulation (CES) and microcurrent electrical therapy (MET) and is supported by over 100 clinical studies. The company operates a direct-to-consumer and healthcare provider sales model, targeting the large and growing market for non-pharmacological treatments in mental health and pain management. While commercially successful, it faces risks from regulatory scrutiny and competition in the digital therapeutic space.

About Pyrexar Medical

Pyrexar Medical, founded in 2008 and headquartered in Salt Lake City, Utah, is a private company commercializing hyperthermia therapy devices for oncology. Its core technology uses phased-array RF antennas to deliver localized, image-guided heat to tumors, a modality supported by Level 1 clinical evidence for several cancer types. While the company generates revenue from sales of certain systems internationally, its advanced BSD-2000 3D/MR platform, which integrates real-time MR thermometry, is not yet available in the U.S. market, representing a significant regulatory and commercial hurdle. Pyrexar's strategy is to position hyperthermia as a synergistic, low-toxicity adjunct to standard cancer care.

About INVO Fertility

INVO Fertility's mission is to address the global infertility crisis by democratizing access to high-quality fertility care. Its core achievement is the development and commercialization of the INVOcell system, a paradigm-shifting technology that enables fertilization and early embryo development within the woman's body, dramatically lowering the cost and complexity of IVF. The company's strategy is dual-pronged: scaling its patient-centric INVO Centers and licensing its technology to established clinics worldwide to drive rapid adoption and market penetration.

Therapeutic Areas